Myeloma Trial Results Spark Talk of ‘Potential Cure’

(MedPage Today) — CHICAGO — A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) improved long-term survival among patients with heavily pretreated relapsed/refractory multiple…